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was atypical leiomyoma with cytologic atypia of the symplastic type
(Fig. 1). The histopathologic diagnosis was conﬁrmed by external re-
view of an independent pathologist. The patient did well following sur-
gery and was discharged. Twenty-two months later, she presented to
the ofﬁce with complaint of a vaginal mass that had been growing
over a few months. A 5-6 cm submucosal, well-demarcated, spherical,
mobile, non-tender mass was appreciated arising from the posterior
aspect of the vagina at the level of the hymenal ring. She underwent re-
section of the mass. The specimen was removed via posterior
colporrhaphy. The specimenwas noted to be cystic and soft with appar-
ent degenerative necrosis. The entire mass was removed; however it
was removed in a piecemeal fashion due to the soft and friable nature1. Introduction
Recurrent, atypical leiomyoma following hysterectomy is rare. Fur-
thermore, recurrence in the form of leiomyosarcoma is even less com-
mon. Treatment recommendations as well as prognosis are based on
expert-opinion and case reports.2. Case report
Our patient presented as a 53 year-old gravida 0with a history of en-
larging ﬁbroids, menorrhagia and an abnormal Pap smear, AS-CUS can-
not rule out ASC-H. A colposcopy revealed HGSIL and an ECC showed
LGSIL. Her medical history is signiﬁcant for colitis and hypothyroidism.
She had an ultrasound that revealed an enlarged uterus including a
new ﬁbroid compared to an ultrasound one year prior. The uterusmea-
sured 17.9 × 10.7 × 13.7 cm. She desired deﬁnitive treatment. An endo-
metrial biopsy was benign. She underwent a robotically-assisted total
laparoscopic hysterectomy with bilateral salpingo-oophorectomy with
a mini-laparotomy for specimen retrieval. The specimen was not
morcellated either in bag or intra-abdominally. A Rumi-KOH uterinet.
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. This is an open access article underof the tumor. The ﬁnal pathologic diagnosis was a low to intermediate
grade leiomyosarcoma with margins favored to be positive (Supple-
mental S1). The same external pathologist was consulted as in the
patient's ﬁrst surgery and there was again agreement upon this histo-
pathologic diagnosis. The original specimen slides were available and
were re-reviewed and the tumors were felt to be different histologically
such that the leiomyosarcoma arising in the vagina represented a recur-
rence of the original disease via transformation of a symplastic atypical
leiomyoma into a leiomyosarcoma. The patient underwent a PET/CT,
which was negative for metastatic disease. Whole pelvic and vaginal
brachytherapy was recommended but patient declined. The treating
physician and patient agreed upon chemotherapy. She completed four
cycles of a chemotherapy regimen consisting of gemcitabine 750 mg/
m2 on days 1 and 8 as well as docetaxel 75 mg/m2 on day 8 every
21 days.3. Discussion
Leiomyosarcoma in the vagina presenting as a recurrence from atyp-
ical uterine leiomyomas, as far aswe are aware, has not been previously
reported. The diagnosis of primary vaginal leiomyosarcoma is rare and
represents 2–3% of vaginal cancers (Curtin et al., 1995). The original
pathologic specimen showed areas of smooth muscle neoplasm inter-
spersed with foci of bizzare, atypical cells. No mitotic ﬁgures or
coagulative necrosis was present. Based on theWorld Health Organiza-
tion revised criteria this patient's original tumor met criteria for the
smooth muscle tumor of uncertain malignant potential (STUMP) sub-
group of ‘atypical leiomyoma with limited experience’ due to lack of
tumor cell necrosis and less than 10 mitotic ﬁgures per high poweredthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. This image at 200× magniﬁcation shows an atypical leiomyoma due to diffuse
cytologic atypia of the symplastic type/bizarre atypia. There is no evidence of coagulative
necrosis and no increased mitotic activity and this did not meet the criteria for
leiomyosarcoma.
5E.J. Cooney et al. / Gynecologic Oncology Reports 14 (2015) 4–5ﬁeld (Ip et al., 2010). The vaginal lesion was hypercellular with a high
mitotic count among moderate cytologic atypia and no coagulative ne-
crosis thus favoring diagnosis of leiomyosarcoma based on the WHO
classiﬁcation system.
Due to its uncommon occurrence, the presenting symptoms of a
leiomyosarcoma arising from or metastatic to the vaginal submucosa
are not well described. Our patient's complaint was related to mass ef-
fect due to the size and location of her lesion. She did not complain of
pain, discharge or abnormal bleeding. Malignant tumors that develop
in the vagina have a predilection for the posterior wall (Curtin et al.,
1995).
Recurrence risk for atypical leiomyoma including STUMP has
been assessed in retrospective studies. A case-study of 51 atypical
leiomyomas identiﬁed 1 case treated with hysterectomy that recurred
with retroperitoneal atypical leiomyoma following an average of 42
months follow-up (Ly et al., 2013). A review by Ip and colleagues (Ip
et al., 2010) included bizarre or symplastic leiomyoma under the head-
ing ‘little or no recurrent and/ormetastatic potential’ and based diagno-
sis on that of the Stanford criteria. They site a Stanford study examining
46 cases of atypical leiomyomas of which 4 recurred. Various mitotic
counts were observed in the recurrent cases indicating it may not be a
reliable predictor of recurrence risk in atypical leiomyomas (Ip et al.,
2010). A review of 24 cases of bizarre leiomyoma did not identify any
recurrences in all cases with a mean follow-up of 11.2 years (Downes
& Hart, 1997). A retrospective evaluation of 67 cases of leiomyosarcoma
identiﬁed 20 cases that did not meet current diagnostic criteria for
leiomyosarcoma andwere reclassiﬁed as atypical or benign leiomyoma.
Of the 18 atypical leiomyoma cases, 3 had recurrence resulting in death.
Recurrences occurred between6 and 11years following initial diagnosis
(Giuntoli et al., 2007). None of these studies identiﬁed leiomyosarcoma
at the time of recurrence of atypical leiomyoma. It is unclear whatproduced the recurrence in our patient as her specimen was removed
through an abdominal mini-laparotomy and the leiomyoma was not
entered during the hysterectomy. The possibility exists that the Rumi-
KOH may have seeded the vagina as it was removed following the
hysterectomy.
Treatment of leiomyosarcoma arising in the vagina is currently
based on expert opinion and should be guided by staging and histologic
grading. Vaginal sarcomas should be clinically staged based on FIGO rec-
ommendations for vaginal cancers. However, our patient was classiﬁed
as recurrence of leiomyoma and was treated as such. Treatment of
leiomyosarcoma in the vagina should include primary surgical resection
with a wide margin followed by radiation plus or minus chemotherapy
(Curtin et al., 1995). Studies examining the use of gemcitabine with do-
cetaxel have shown objective response in patients with metastatic
leiomyosarcoma as ﬁrst-line therapy (Hensley et al., 2008). After a
multi-disciplinary team met to discuss treatment options our patient
was offered chemotherapy with radiation. She declined radiation. Her
recommended follow-up was every 3 months to include history and
physical exam with symptom-based imaging. A review on soft-tissue
sarcomas noted a 70% survival at 5-years and found a favorable outcome
when a low-grade sarcoma was diagnosed compared to high-grade.
This review included various histologic subtypes and thus may not be
applicable to leiomyosarcomas speciﬁcally. Additionally, they noted a
trend towards high-grade sarcomas recurring as distant metastases as
opposed to locally (Curtin et al., 1995).
The recurrence risk of atypical leiomyomas is still poorly understood.
We have presented a case here in which bizarre, atypical leiomyomas
recurred as leiomyosarcoma in the vagina. Our patient has remained
disease free in the 11 months since surgery.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.gore.2015.07.006.
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